We recently published a list of 11 Best stocks of medical devices to buy now. In this article, we are going to examine where Johnson & Johnson (NYSE: JNJ) is against other best medical actions to buy now.
On April 16, CNBC reported that Trump’s prices built a fracture in the medical community. The first Trump administration did not impose rates on medical devices and protective equipment manufactured in Mexico, China and Canada. However, the sector has not received suspended from the president’s latest series of tasks so far. This resulted in a division: since the manufacturers of devices could potentially face important challenges of prices, they repel for a way out. On the other hand, manufacturers of personal protective equipment benefit from the obstacles created by the samples, which is why they do not show signs of regrowth.
The medical community thus presents a dichotomy in the face of prices. CNBC has indicated that tasks could also increase costs for hospitals and, in turn, patients, ultimately reducing access to intensive care and equipment. Scott Whitaker, CEO of Advamed, the commercial group representing medical technology and apparatus manufacturers, said the following on the situation:
“Medtech supply chain leaders already report supply chain problems, and we cannot afford to increase the cost of health care for patients or on the health care system. The reality is that increased costs will be largely borne by health programs funded by taxpayers such as Medicare, Medicaid and VA. ”
Hospital trade groups also express their concerns, warning that prices could reduce the quality of care. CNBC reported that Rick Pollack, CEO of the American Hospital Association, estimated:
“AHA A and will continue to share with the administration, disturbances in the availability of these critical devices – many of which come international – have the potential to disrupt patient care. AHA continues to put pressure for a price exemption for medical devices to ensure that hospitals and health systems can continue to serve their patients and communities. ”
President Trump imposed a 25% rate on goods imported from Mexico and Canada in February, later delaying samples from a certain number of articles under the American-Mexican-Canada agreement. However, Chinese products have not seen any stay. In fact, the new samples imposed on the second term of Trump brought the total rate rate to 145%. While a means of getting out of the current conditions is to increase prices to compensate for the increase in pricing expenses, a range of hospitals and other organizations buying medical equipment cannot do so. These institutions are therefore likely to deal with complications achieving higher costs under current insurance coverage contracts with enclosed annual prices.
Casey Hite, CEO of Aeroflow Health, a company that provides insurance covered with insurance, said the following:
“With the level of prices we examine in China, companies will be completely upside down on these products … They cannot pass these costs to the consumer. I think what we would like to see, more than anything, is a track or predictability.
We have examined the screening for actions, financial media reports and ETFs to compile a list of the 25 best medical devices, then chose the Top 11 with the largest number of hedge holders in the fourth quarter 2024. We provided the data of feeling funds of cover of the database of the initiate Monkey. The list is ordered in an increasing order of feeling of hedge funds.
Why are we interested in the stocks in which the hedge funds stacked? The reason is simple: our research has shown that we can surpass the market by imitating the main choices of stock of the best hedge funds. The strategy of our quarterly newsletter selects 14 shares with small capitalization and large capitalization each quarter and has rendered 363.5% since May 2014, beating its reference with 208 percentage points (See more details here).
Johnson & Johnson (JNJ) is Dow’s best stock?
A baby smiling with a range of baby care products in the foreground.
Number of hedge holders: 98
Johnson & Johnson (NYSE: JNJ) develops, manufactures and sells products in the field of health care. The company operates through two segments: innovative medicine and Medtech. The Medtech segment includes an developed range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery and fields of vision.
On May 1, Leerink Partners’ analyst David Risinger maintained his upward position on the action, which gives him a purchase note because of the promising developments of his TAR-200 platform for the treatment of bladder cancer. The Sunrise-1 Cohort 4 study reported strong data, which highlights the significant potential of Tar-200 to be considered as a preferred treatment option. He could even replace more invasive procedures such as radical cystectomy, and also has a favorable security profile.
Given that many patients with bladder cancer fall into the non -muscular invasive category, the important market opportunity also supports the positive prospects of Johnson & Johnson (NYSE: JNJ). Management believes that advanced sales for the Taris platform to exceed $ 5 billion, suggesting a solid income potential.
Johnson & Johnson (NYSE: JNJ) also plans to request a strategic approval in 2026, which further justifies the purchase note for the action.
Overall, Jnj rank On our list of the best medical actions to buy now. While we recognize JNJ’s potential as an investment, our conviction lies in the conviction that certain AI actions are more promising to provide higher yields and do it within a shorter period. There is a stock of AI that has increased since the beginning of 2025, while the popular AI shares have lost around 25%. If you are looking for a more promising actions than JNJ but which is negotiated within 5 times its income, consult our report on this subject Stock ai the cheapest.
